Enhanced cognitive function
anecdotal
0 views
Adamax
Adamax is a synthetic nootropic peptide and enhanced derivative of Semax, featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration.
Overview
Adamax is a synthetic nootropic peptide and enhanced derivative of Semax, featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration. It's researched for cognitive enhancement, neuroprotection, neuroplasticity, and potential therapeutic applications in stroke recovery and mood disorders.
Last reviewed: 2026-08-18
Identity & Aliases
Also known as
Semax analogadamantane-modified semaxN-phenylacetyl ACTH-derived peptide derivative
Status: Research compound - experimental peptide with limited human research data
Full composition (formula, molecular weight, sequence) in Quick Facts →
Research Areas
Cognitive enhancement (nootropic research)NeuroprotectionBDNF/NGF signaling (claimed)
Available Evidence
Uncertain
No peer-reviewed clinical, animal, or in-vitro studies of adamax itself were located. Most information circulating (BDNF/NGF upregulation, nootropic and neuroprotective effects) comes from peptide vendor catalogs, forums, and extrapolation from the parent compound semax, a registered Russian drug. These claims are unverified in the indexed published literature.
Benefits & Effects
improved focus and mental clarity
anecdotal
neuroprotection
anecdotal
neuroplasticity support
anecdotal
potential mood enhancement
anecdotal
stress resilience
anecdotal
Superior bioavailability through direct systemic delivery
anecdotal
No side effects data available yet.
This peptide may have limited safety data.
Limitations & Open Questions
Adamax has essentially no published evidence base: no indexed clinical trials, no animal efficacy studies, and no peer-reviewed in-vitro data were found in this review. Its profile is inferred from semax (which itself has mostly Russian-language clinical data) and from proprietary or vendor descriptions. Any use is experimental.
Reported Research Dosing
Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.
200-300mcg
Route: Injectable
Half-life: 6-8 hours (extended vs. parent Semax)
Research Protocols
Cognitive enhancement
- Dose
- 200-300mcg
- Frequency
- 1x daily
- Route
- SubQ
Neuroprotection
- Dose
- 300mcg
- Frequency
- 1-2x daily
- Route
- SubQ
Mood support
- Dose
- 200mcg
- Frequency
- 1x daily (morning)
- Route
- SubQ
Initial trial/assessment
- Dose
- 100-200mcg
- Frequency
- 1x daily
- Route
- SubQ
Research protocols are for educational purposes only. Always consult qualified medical professionals.
Frequently Asked Questions
Is adamax the same as semax?
No. Adamax is a synthetic derivative of semax (an ACTH(4-7)-derived heptapeptide) modified with an adamantane group, intended to improve stability or potency. No published comparative pharmacology was located.
Has adamax been studied in humans?
No published clinical trials of adamax were found in PubMed or clinical trial registries as of this review.
Is adamax approved by any regulator?
No. It is not FDA-approved and has no registered medicinal status found in this review; it is marketed only as a research compound.
Research Citations
1
Adamax Stroke Recovery Preliminary Reports
()
2
BDNF and TrkB Receptor Upregulation Studies
()
3
Neurotransmitter Modulation in Cognitive Enhancement
()
Related Resources
Quick Facts
Molecular Weight
1032.24
Mechanism
Adamax crosses the blood-brain barrier via enhanced lipophilicity from adamantane modification. It upregulates BDNF and TrkB receptor sensitivity, modulates dopamine, norepinephrine, and serotonin levels, stabilizes microtubules through ADNP-derived mechanisms, and provides antioxidant and anti-inflammatory neuroprotection.
Safety Information
Use sterile injection technique to prevent infection. CRITICAL: This is an experimental peptide with limited human research data. Start with lower doses (100-200mcg) to assess individual response. Monitor for cardiovascular effects (increased blood pressure, heart palpitations). Cycle usage with breaks to prevent potential tolerance development. Not recommended during pregnancy or breastfeeding. Consult healthcare provider before use, especially with cardiovascular conditions. All reported benefits are primarily anecdotal and individual.
Citations
31.Adamax Stroke Recovery Preliminary Reports
()
2.BDNF and TrkB Receptor Upregulation Studies
()
3.Neurotransmitter Modulation in Cognitive Enhancement
()